What es

AELMHU?

We are a non-profit association made up of pharmaceutical companies, specialised in rare diseases, that are committed to discovering, researching, developing and commercialising innovative therapies that improve the lives of patients and their families.

RESEARCH AND COMMITMENT to rare diseases

MEMBERS

Do you want to be part of AELMHU?

What is a orphan drug?

Orphan drugs ( ODM) are innovative treatments, many of them of biotechnological origin, intended to establish a diagnosis, prevent or treat patients with rare or minority diseases for which there is no therapeutic alternative.

AccessReport

AELMHU prepares, on a quarterly and annual basis,
reports on access to orphan drugs in Spain.

Check the latest update

Advanced therapies for rare diseases

NEWS

NEWS

AELMHU, represented by its director, Marian Corral, has collaborated and participated in the event organized by Bioinnova Consulting at the University Carlos III of Madrid, with the aim of addressing "The future of the therapies ... Read more

New clinical trial report at
rare diseases

First quarterly access report 2023 for orphan drugs

AELMHU's contributions to the new public consultation of the Ministry of Health.

AELMHU's contributions to the new public consultation of the Ministry of Health.

Assessments and proposals for access to orphan drugs in Spain.

Assessments and proposals for access to orphan drugs in Spain.

TWITTER

History, current situation and future perspectives of neonatal screening for rare diseases in Spain
Interview with Álvaro Hidalgo, President of the Weber Foundation

ASSOCIATED COMPANIES